We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mirati Therapeutics Inc | NASDAQ:MRTX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 58.70 | 58.90 | 58.70 | 0 | 01:00:00 |
From Jun 2023 to Jun 2024
10:00 ET -- Bristol Myers Squibb is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Bristol Myers Squibb is buying Mirati Therapeutics in a deal that values the oncology developer at up to $5.8 billion. The biopharmaceutical company on Sunday said that it had entered into a definitive merger agreement with Mirati under which it would pay $58.00 a share in cash. Mirati stockholders will also receive one non-tradable contingent value right per share, potentially worth $12.00 a share in cash. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com)
(END) Dow Jones Newswires
October 09, 2023 10:15 ET (14:15 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Mirati Therapeutics Chart |
1 Month Mirati Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
